Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

Giskeødegård GF, Bertilsson H, Selnæs KM, Wright AJ, Bathen TF, Viset T, Halgunset J, Angelsen A, Gribbestad IS, Tessem MB.

PLoS One. 2013 Apr 23;8(4):e62375. doi: 10.1371/journal.pone.0062375. Print 2013.

PMID:
23626811
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.

Selnaes KM, Gribbestad IS, Bertilsson H, Wright A, Angelsen A, Heerschap A, Tessem MB.

NMR Biomed. 2013 May;26(5):600-6. doi: 10.1002/nbm.2901. Epub 2012 Dec 27.

PMID:
23280546
[PubMed - indexed for MEDLINE]
3.

Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples.

Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, Halgunset J.

Clin Cancer Res. 2012 Jun 15;18(12):3261-9. doi: 10.1158/1078-0432.CCR-11-2929. Epub 2012 Apr 17.

PMID:
22510345
[PubMed - indexed for MEDLINE]
Free Article
4.

In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil.

Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TW.

Eur Urol. 2011 Nov;60(5):1074-80. doi: 10.1016/j.eururo.2011.03.002. Epub 2011 Mar 17.

PMID:
21419565
[PubMed - indexed for MEDLINE]
5.

Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.

Aydin H, Kizilgöz V, Tatar IG, Damar C, Ugan AR, Paker I, Hekimoğlu B.

J Comput Assist Tomogr. 2012 Jan-Feb;36(1):30-45. doi: 10.1097/RCT.0b013e31823f6263.

PMID:
22261768
[PubMed - indexed for MEDLINE]
6.

The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.

Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED.

Prostate. 2008 May 1;68(6):620-8. doi: 10.1002/pros.20727.

PMID:
18213632
[PubMed - indexed for MEDLINE]
7.

Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.

Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL.

Cancer Res. 2005 Apr 15;65(8):3030-4.

PMID:
15833828
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.

Dittrich R, Kurth J, Decelle EA, DeFeo EM, Taupitz M, Wu S, Wu CL, McDougal WS, Cheng LL.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):278-82. doi: 10.1038/pcan.2011.70. Epub 2012 Jan 31.

PMID:
22289782
[PubMed - indexed for MEDLINE]
10.

HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.

Choi JS, Baek HM, Kim S, Kim MJ, Youk JH, Moon HJ, Kim EK, Han KH, Kim DH, Kim SI, Koo JS.

PLoS One. 2012;7(12):e51712. doi: 10.1371/journal.pone.0051712. Epub 2012 Dec 14.

PMID:
23272149
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores.

Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, King CR, Verma G, Sayre J, Reiter RE, Thomas MA.

J Magn Reson Imaging. 2012 Sep;36(3):697-703. doi: 10.1002/jmri.23676. Epub 2012 May 11.

PMID:
22581787
[PubMed - indexed for MEDLINE]
12.

Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G.

Radiol Med. 2008 Aug;113(5):670-88. doi: 10.1007/s11547-008-0271-8. Epub 2008 May 20. English, Italian.

PMID:
18493829
[PubMed - indexed for MEDLINE]
13.

MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.

Hasumi M, Suzuki K, Oya N, Ito K, Kurokawa K, Fukabori Y, Yamanaka H.

Anticancer Res. 2002 Mar-Apr;22(2B):1205-8.

PMID:
12168926
[PubMed - indexed for MEDLINE]
14.

Metabolomic signatures of aggressive prostate cancer.

McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, Lotan Y, Wheeler TM.

Prostate. 2013 Oct;73(14):1547-60. doi: 10.1002/pros.22704. Epub 2013 Jul 3.

PMID:
23824564
[PubMed - indexed for MEDLINE]
Free Article
15.

Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.

Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS.

NMR Biomed. 2010 May;23(4):424-31. doi: 10.1002/nbm.1478. Epub 2010 Jan 25.

PMID:
20101607
[PubMed - indexed for MEDLINE]
16.

Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies.

Mirnezami R, Jiménez B, Li JV, Kinross JM, Veselkov K, Goldin RD, Holmes E, Nicholson JK, Darzi A.

Ann Surg. 2014 Jun;259(6):1138-49. doi: 10.1097/SLA.0b013e31829d5c45.

PMID:
23860197
[PubMed - indexed for MEDLINE]
17.

1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication.

Jiménez B, Mirnezami R, Kinross J, Cloarec O, Keun HC, Holmes E, Goldin RD, Ziprin P, Darzi A, Nicholson JK.

J Proteome Res. 2013 Feb 1;12(2):959-68. doi: 10.1021/pr3010106. Epub 2013 Jan 16.

PMID:
23240862
[PubMed - indexed for MEDLINE]
18.

Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.

Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J.

Magn Reson Med. 2008 Sep;60(3):510-6. doi: 10.1002/mrm.21694.

PMID:
18727052
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van de Kaa CA, Barentsz JO, Heerschap A, Scheenen TW.

Radiology. 2012 Nov;265(2):457-67. doi: 10.1148/radiol.12111744. Epub 2012 Jul 27.

PMID:
22843767
[PubMed - indexed for MEDLINE]
20.

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.

Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB.

J Magn Reson Imaging. 2002 Oct;16(4):451-63. Review.

PMID:
12353259
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk